Suvankar Majumdar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7885347/publications.pdf

Version: 2024-02-01

40 papers

1,774 citations

687363 13 h-index 32 g-index

40 all docs 40 docs citations

40 times ranked

2431 citing authors

#	Article	IF	Citations
1	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. New England Journal of Medicine, 2017, 377, 2215-2227.	27.0	549
2	Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia. New England Journal of Medicine, 2014, 371, 699-710.	27.0	421
3	A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. New England Journal of Medicine, 2016, 374, 2054-2064.	27.0	414
4	Overweight and Obesity in Hemophilia. American Journal of Preventive Medicine, 2011, 41, S369-S375.	3.0	58
5	Multisystem Inflammatory Syndrome of Children: Subphenotypes, Risk Factors, Biomarkers, Cytokine Profiles, and Viral Sequencing. Journal of Pediatrics, 2021, 237, 125-135.e18.	1.8	40
6	The use and effectiveness of complementary and alternative medicine for pain in sickle cell anemia. Complementary Therapies in Clinical Practice, 2013, 19, 184-187.	1.7	30
7	Malaria, Epstein–Barr virus infection and the pathogenesis of Burkitt's lymphoma. International Journal of Cancer, 2017, 141, 1849-1855.	5.1	25
8	Quality of life among pediatric patients with cancer: Contributions of time since diagnosis and parental chronic stress. Pediatric Blood and Cancer, 2015, 62, 1232-1236.	1.5	24
9	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2021, 325, 1513.	7.4	24
10	Spk-9001: Adeno-Associated Virus Mediated Gene Transfer for Hemophilia B Achieves Sustained Mean Factor IX Activity Levels of >30% without Immunosuppression. Blood, 2016, 128, 3-3.	1.4	24
11	Compound heterozygous mutation with a novel splice donor region DNA sequence variant in the succinate dehydrogenase subunit B gene in malignant paraganglioma. Pediatric Blood and Cancer, 2010, 54, 473-475.	1.5	17
12	Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Blood, 2015, 126, 5-5.	1.4	16
13	Outcome of overt stroke in sickle cell anaemia, a single institution's experience. British Journal of Haematology, 2014, 165, 707-713.	2.5	15
14	Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: Clinical Features and Risk Factors. Journal of Pediatric Hematology/Oncology, 2018, 40, 51-55.	0.6	12
15	Gender Differences in Incidence Rates of Childhood B-Precursor Acute Lymphocytic Leukemia in Mississippi. Journal of Pediatric Oncology Nursing, 2010, 27, 164-167.	1.5	11
16	Successful Prophylactic Treatment for Bleeding in a Girl With Severe Hereditary Prothrombin Deficiency Using a Prothrombin Complex Concentrate (Bebulin® VH). Journal of Pediatric Hematology/Oncology, 2004, 26, 480-483.	0.6	10
17	Daily Pain, Physical Activity, and Home Fluid Intake in Pediatric Sickle Cell Disease. Journal of Pediatric Psychology, 2016, 42, jsw061.	2.1	10
18	A phase 1 doseâ€finding study of intravenous Lâ€citrulline in sickle cell disease: a potential novel therapy for sickle cell pain crisis. British Journal of Haematology, 2019, 184, 634-636.	2.5	10

#	Article	IF	Citations
19	Stroke with intracranial stenosis is associated with increased platelet activation in sickle cell anemia. Pediatric Blood and Cancer, 2013, 60, 1192-1197.	1.5	9
20	Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes. American Journal of Hematology, 2018, 93, 760-768.	4.1	8
21	Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke. Transplantation and Cellular Therapy, 2021, 27, 1018.e1-1018.e9.	1.2	7
22	Inhaled corticosteroid use to prevent severe vasoâ€occlusive episode recurrence in children between 1 and 4 years of age with sickle cell disease: a multicenter feasibility trial. American Journal of Hematology, 2018, 93, E101-E103.	4.1	6
23	Outcome of Hematopoietic Cell Transplantation in Children with Sickle Cell Disease, a Single Center's Experience Blood, 2007, 110, 1112-1112.	1.4	6
24	A Rare Case of Peripheral Neuropathy From Relapse of Acute Lymphoblastic Leukemia to the Brachial Plexus. Journal of Pediatric Hematology/Oncology, 2012, 34, e77-e79.	0.6	5
25	Associations among emergency room visits, parenting styles, and psychopathology among pediatric patients with sickle cell. Pediatric Blood and Cancer, 2014, 61, 1822-1827.	1.5	5
26	Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project. Transfusion Medicine, 2020, 30, 226-230.	1.1	5
27	Platelet activation and erythrocyte lysis during brief exposure of blood to pathophysiological shear stress in vitro. Clinical Hemorheology and Microcirculation, 2017, 67, 159-172.	1.7	4
28	Phase 3 Study of L-Glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events. Blood, 2017, 130, 685-685.	1.4	3
29	Concordance with comprehensive iron assessment, hepatitis A vaccination, and hepatitis B vaccination recommendations among patients with sickle cell disease and thalassaemia receiving chronic transfusions: an analysis from the Centers for Disease Control haemoglobinopathy blood safety project. British Journal of Haematology, 2021, 195, e160-e164.	2.5	2
30	The Adolescent with Sickle Cell Disease. , 2013, , 295-306.		1
31	Pediatric Sickle Cell Disease and the COVID-19 Pandemic: A Year in Review at Children's National Hospital. Blood, 2021, 138, 3036-3036.	1.4	1
32	The adolescent with sickle cell disease. Adolescent Medicine: State of the Art Reviews, 2013, 24, 295-306, xv.	0.2	1
33	An Update on Sickle Cell Anemia in Children and Adolescents. Journal of the Mississippi State Medical Association, 2015, 56, 268-71.	0.1	1
34	What are the mechanisms of tumor formation in patients with paraganglioma and <i>SDHB</i> germline mutations?. Pediatric Blood and Cancer, 2010, 55, 212-212.	1.5	0
35	1225. Critical Care Medicine, 2014, 42, A1646.	0.9	0
36	Malaria, Epstein–Barr virus, vitamin A and Burkitt's lymphoma: Response to Joob and Wiwanitkit. International Journal of Cancer, 2018, 142, 864-864.	5.1	0

#	Article	IF	CITATIONS
37	Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study. Blood, 2018, 132, 384-384.	1.4	O
38	Assessment of Iron Overload Impact on QTc Interval in Patients with Sickle Cell Disease. Blood, 2018, 132, 3673-3673.	1.4	0
39	542. SARS CoV-2-Associated Multisystem Inflammatory Syndrome of Children (MIS-C) in the Washington DC Metropolitan Region. Open Forum Infectious Diseases, 2020, 7, S338-S338.	0.9	O
40	Complementary and Integrative Medicine Use in Pediatric Patients with Sickle Cell Disease., 2022, 1, 24-28.		0